GSK-3

Glycogen synthase kinase-3; Glycogen synthase kinase 3

Glycogen synthase kinase 3 (GSK-3) is a multifunctional serine/threonine kinase found in all eukaryotes. GSK-3 is one of the few signaling mediators that play central roles in a diverse range of signaling pathways, including those activated by Wnts, hedgehog, growth factors, cytokines, and G protein-coupled ligands. GSK-3 targets transcription factors, regulates the activity of metabolic and signaling enzymes, and controls the half-life of proteins by earmarking them for degradation. GSK-3 exists as two isoforms, GSK-3a (51 kDa) and GSK3b (47 kDa), which are encoded by distinct genes. These isoforms often have overlapping functions, but they do not always compensate for each other.



Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

GSK-3 Inhibitors

(R)-BRD3731

Cat. No.: HY-124607

(R)-BRD3731 is a **GSK3** inhibitor extracted from patent US20160375006A1, compound example 273, has IC_{50}s of 1.05 and 6.7 μM for **GSK3β** and **GSK3α**, respectively.



Purity: 98.22%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

1-Azakenpaullone

(1-Akp)

Cat. No.: HY-59090

1-Azakenpaullone (1-Akp) is a highly selective and ATP-competitive inhibitor of **glycogen synthase kinase-3 β (GSK-3β)**, with an IC_{50} value of 18 nM.



Purity: 98.20%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg

2B-(SP)

Cat. No.: HY-P1114

2B-(SP) is a eIF2B-based substrate for glycogen synthase kinase-3 (**GSK-3**). 2B-(SP) is readily phosphorylated by both the α and β isoforms of GSK-3.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

2B-(SP) (TFA)

Cat. No.: HY-P1114A

2B-(SP) TFA is a eIF2B-based substrate for glycogen synthase kinase-3 (**GSK-3**). 2B-(SP) TFA is readily phosphorylated by both the α and β isoforms of GSK-3.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

5-Iodo-indirubin-3'-monoxime

Cat. No.: HY-111930

5-Iodo-indirubin-3'-monoxime is a potent **GSK-3β**, **CDK5/P25** and **CDK1/cyclin B** inhibitor, competing with ATP for binding to the catalytic site of the kinase, with IC_{50}s of 9, 20 and 25 nM, respectively.



Purity: 99.50%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

9-ING-41

Cat. No.: HY-113914

9-ING-41 is a potent **glycogen synthase kinase-3 (GSK-3)** inhibitor. 9-ING-41 induces apoptosis and cell cycle arrest at prophase by targeting centrosomes and microtubule-bound GSK-3β. 9-ING-41 has anticancer activity.



Purity: 99.32%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

A 1070722

Cat. No.: HY-107531

A 1070722 is a potent and selective **glycogen synthase kinase 3 (GSK-3)** inhibitor, with a K_i of 0.6 nM for both GSK-3α and GSK-3β.



Purity: 99.48%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

Alsterpaullone

(9-Nitropaullone; NSC 705701)

Cat. No.: HY-108359

Alsterpaullone (9-Nitropaullone) is a potent **CDK** inhibitor, with IC_{50}s of 35 nM, 15 nM, 200 nM and 40 nM for CDK1/cyclin B, CDK2/cyclin A, CDK2/cyclin E and CDK5/p35, respectively.



Purity: 97.30%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg

AR-A014418

(AR 0133418; GSK 3β inhibitor VIII; AR 014418)

Cat. No.: HY-10512

AR-A014418 is a potent, selective and ATP-competitive **GSK3β** inhibitor with an IC_{50} of 104 nM.



Purity: 99.49%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AZD1080

Cat. No.: HY-13862

AZD1080 is a potent and selective **GSK3** inhibitor. AZD1080 inhibits recombinant human **GSK3α** and **GSK3β** with pK_i (IC_{50}) of 8.2 (6.9 nM) and 7.5 (31 nM), respectively.



Purity: 99.46%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AZD2858

Cat. No.: HY-15761

AZD2858 is a potent, orally active **GSK-3** inhibitor, with IC_{50}s of 0.9 and 5 nM for **GSK-3α** and **GSK-3β**, respectively, used in the research of fracture healing.



Purity: 99.24%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

Bikinin

(Abrasin)

Cat. No.: HY-12524

Bikinin is a non-steroidal, ATP-competitive inhibitor of plant **GSK-3/Shaggy-like kinases** and activates BR (brassinosteroids) signaling.



Purity: 99.94%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BIO-acetoxime

(BIA)

Cat. No.: HY-15356

BIO-acetoxime (BIA) is a potent and selective **GSK-3** inhibitor, with IC_{50}s of both 10 nM for GSK-3α/β. BIO-acetoxime has anticonvulsant and anti-infection activity.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BIP-135

Cat. No.: HY-111055

BIP-135 is a potent and selective ATP-competitive **GSK-3** inhibitor, with IC_{50}s of 16 nM and 21 nM for GSK-3α and GSK-3β, respectively. BIP 135 exhibits neuroprotective effect.



Purity: 98.31%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

BRD0705

Cat. No.: HY-116830

BRD0705 is a potent, paralog selective and orally active **GSK3α** inhibitor with an IC_{50} of 66 nM and a K_d of 4.8 μM. BRD0705 displays increased selectivity for **GSK3α** (8-fold) versus GSK3β (IC_{50} of 515 nM). BRD0705 can be used for acute myeloid leukemia (AML) research.



Purity: 98.41%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

BRD3731

Cat. No.: HY-124607B

BRD3731 is a selective **GSK3β** inhibitor, with IC_{50}s of 15 nM and 215 nM for GSK3β and GSK3α, respectively. BRD3731 can be used for the research of a mood disorder, post-traumatic stress disorder (PTSD), psychiatric disorder, diabetes, and neurodegenerative disorder.



Purity: 98.02%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

Charantin

Cat. No.: HY-N7261

Charantin is a steroidal saponin isolated from Momordica charantia, and has insulin-like activity, by increasing the release of insulin and slowing down gluconeogenesis. Charantin can against **GSK-3**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CHIR-98014

Cat. No.: HY-13076

CHIR-98014 is a potent, cell-permeable **GSK-3** inhibitor with IC_{50}s of 0.65 and 0.58 nM for **GSK-3α** and **GSK-3β**, respectively; it shows less potent activities against cdc2 and erk2.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

CHIR-99021

(CT99021)

Cat. No.: HY-10182

CHIR-99021 (CT99021) is a potent and selective **GSK-3α/β** inhibitor with IC_{50}s of 10 nM and 6.7 nM. CHIR-99021 shows >500-fold selectivity for **GSK-3** over CDC2, ERK2 and other protein kinases. CHIR-99021 is also a potent **Wnt/β-catenin** signaling pathway activator.



Purity: 99.76%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CHIR-99021 monohydrochloride

(CT99021 monohydrochloride)

Cat. No.: HY-10182A

CHIR-99021 monohydrochloride (CT99021 monohydrochloride) is a potent and selective **GSK-3α/β** inhibitor with IC_{50}s of 10 nM and 6.7 nM. CHIR-99021 monohydrochloride shows >500-fold selectivity for **GSK-3** over CDC2, ERK2 and other protein kinases.



Purity: 99.93%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CHIR-99021 trihydrochloride

(CT99021 trihydrochloride) Cat. No.: HY-10182B

CHIR-99021 trihydrochloride (CT99021 trihydrochloride) is a potent and selective **GSK-3α/β** inhibitor with **IC_{50}**s of 10 nM and 6.7 nM. CHIR-99021 trihydrochloride shows >500-fold selectivity for **GSK-3** over CDC2, ERK2 and other protein kinases.



Purity: 97.93%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

CP21R7

(CP21) Cat. No.: HY-100207

CP21R7 is potent **GSK-3β** inhibitor, with an **IC_{50}** of 1.8 nM; CP21R7 also shows inhibitory activitiy against **PKCα**, with an **IC_{50}** of 1900 nM.



Purity: 99.77%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Cromolyn sodium

(Disodium Cromoglycate; FPL-670) Cat. No.: HY-B0320A

Cromolyn sodium (Disodium Cromoglycate; FPL-670) is an antiallergic drug. Cromolyn sodium is a **GSK-3β** inhibitor with an **IC_{50}** of 2.0 μM.



Purity: 99.10%
Clinical Data: Launched
Size: 500 mg, 1 g, 5 g

EHT 5372

Cat. No.: HY-111380

EHT 5372 is a strong inhibitor of **DYRK's** family kinases, with **IC_{50}s** of 0.22, 0.28 nM for DYRK1A and DYRK1B, respectively.



Purity: 98.07%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

GNF4877

Cat. No.: HY-129492

GNF4877 is a potent **DYRK1A** and **GSK3β** inhibitor with **IC_{50}**s of 6nM and 16nM, respectively, which leads to blockade of nuclear factor of activated T-cells (NFATc) nuclear export and increased β-cell proliferation (**EC_{50}** of 0.66μM for mouse β (R7T1) cells).



Purity: 98.85%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

GSK 3 Inhibitor IX

(6-Bromoindirubin-3'-oxime; BIO; MLS 2052) Cat. No.: HY-10580

GSK 3 Inhibitor IX (6-Bromoindirubin-3'-oxime; BIO) is a potent, selective, reversible and ATP-competitive inhibitor of **GSK-3α/β** and **CDK1-cyclinB** complex with **IC_{50}**s of 5 nM/320 nM/80 nM for (GSK-3α/β)/CDK1/CDK5, respectively.



Purity: 99.66%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

GSK-3 inhibitor 1

Cat. No.: HY-13973A

GSK-3 inhibitor 1 is an inhibitor of **GSK-3**.



Purity: 99.89%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

GSK-3β inhibitor 1

Cat. No.: HY-126144

GSK-3β inhibitor 1 (compound 3a) is a **glycogen synthase kinase 3β (GSK-3β)** inhibitor and demonstrates high antidiabetic efficacy, with an **IC_{50}** of 4.9 nM.



Purity: 98.07%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

GSK-3β inhibitor 2

Cat. No.: HY-130795

GSK-3β inhibitor 2 (Compound 3) is a potent, selective and orally active **GSK-3β** inhibitor with an **IC_{50}** of 1.1 nM. GSK-3β inhibitor 2 can cross the blood-brain barrier. GSK-3β inhibitor 2 has the potential for Alzheimer's disease.



Purity: 98.82%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

GSK3 Substrate, α, β subunit

Cat. No.: HY-P2558

GSK3 Substrate, α, β subunit is peptide substrate for glycogen synthase kinase-3 (GSK-3) and can be used to measure GSK-3 activity.

RAAVPPSPSLSRHSSPHQSEDEEE

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

IM-12

Cat. No.: HY-12292

IM-12 is an inhibitor of **GSK-3β**, with an IC_{50} of 53 nM, and also enhances Wnt signalling.



Purity: 98.30%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Indirubin-3'-monoxime

(Indirubin-3'-oxime)

Cat. No.: HY-19807

Indirubin-3'-monoxime is a potent **GSK-3β** inhibitor, and weakly inhibits **5-Lipoxygenase**, with IC_{50}s of 22 nM and 7.8-10 μM, respectively; Indirubin-3'-monoxime also shows inhibitory activities against CDK5/p25 and CDK1/cyclin B, with IC_{50}s of 100 and 180 nM.



Purity: 99.95%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Indirubin-3'-monoxime-5-sulphonic acid

Cat. No.: HY-111931

Indirubin-3'-monoxime-5-sulphonic acid is a potent and selective inhibitor of **CDK1**, **CDK5**, and **GSK-3β** with IC_{50}s of 5 nM, 7 nM, and 80 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

Indirubin-5-sulfonate

Cat. No.: HY-111932

Indirubin-5-sulfonate is a **cyclin-dependent kinase (CDK)** inhibitor, with IC_{50} values of 55 nM, 35 nM, 150 nM, 300 nM and 65 nM for CDK1/cyclin B, CDK2/cyclin A, CDK2/cyclin E, CDK4/cyclin D1, and CDK5/p35, respectively. Indirubin-5-sulfonate also shows inhibitory activity against **GSK-3β**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

K00546

Cat. No.: HY-103647

K00546 is a potent **CDK1** and **CDK2** inhibitor with IC_{50}s of 0.6 nM and 0.5 nM for **CDK1/cyclin B** and **CDK2/cyclin A**, respectively. K00546 is also a potent **CDC2-like kinase 1 (CLK1)** and **CLK3** inhibitor with IC_{50}s of 8.9 nM and 29.2 nM, respectively.



Purity: 98.78%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Kenpaullone

(9-Bromopaullone; NSC-664704)

Cat. No.: HY-12302

Kenpaullone is a potent inhibitor of **CDK1/cyclin B** and **GSK-3β**, with IC_{50}s of 0.4 μM and 23 nM, and also inhibits CDK2/cyclin A, CDK2/cyclin E, and CDK5/p25 with IC_{50}s of 0.68 μM, 7.5 μM, 0.85 μM, respectively.



Purity: 98.07%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

KY19382

(A3051)

Cat. No.: HY-131447

KY19382 is a potent and orally active dual inhibitor of **CXXC5-DVL** and **GSK3β**, with IC_{50}s of 19 and 10 nM, respectively. KY19382 activates Wnt/β-catenin signaling through inhibitory effects on both CXXC5-DVL interaction and GSK3β activity.



Purity: 95.53%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

LY2090314

Cat. No.: HY-16294

LY2090314 is a potent inhibitor of **glycogen synthase kinase-3 (GSK-3)** with IC_{50} values of 1.5 nM and 0.9 nM for GSK-3α and GSK-3β, respectively.



Purity: 99.01%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Phospho-Glycogen Synthase Peptide-2(substrate)

Cat. No.: HY-P1113

Phospho-Glycogen Synthase Peptide-2 (substrate) is peptide substrate for glycogen synthase kinase-3 (**GSK-3**) and can be used for affinity purification of protein-serine kinases.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Phospho-Glycogen Synthase Peptide-2(substrate) TFA

Cat. No.: HY-P1113A

Phospho-Glycogen Synthase Peptide-2 (substrate) is peptide substrate for glycogen synthase kinase-3 (**GSK-3**) and can be used for affinity purification of protein-serine kinases.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

R547

Cat. No.: HY-10014

R547 is a potent, selective and oral orally bioavailable ATP-competitive **CDK** inhibitor, with K_is of 2 nM, 3 nM and 1 nM for CDK1/cyclin B, CDK2/cyclin E and CDK4/cyclin D1, respectively.



Purity: 99.66%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

RGB-286638

Cat. No.: HY-15504

RGB-286638 is a **CDK** inhibitor that inhibits the kinase activity of **cyclin T1-CDK9**, **cyclin B1-CDK1**, **cyclin E-CDK2**, **cyclin D1-CDK4**, **cyclin E-CDK3**, and **p35-CDK5** with IC_{50}s of 1, 2, 3, 4, 5 and 5 nM, respectively; also inhibits GSK-3β, TAK1, Jak2 and MEK1, with IC_{50}s of 3, 5, 50, and 54 nM.



Purity: 98.72%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

RGB-286638 free base

Cat. No.: HY-15504A

RGB-286638 is a **CDK** inhibitor that inhibits the kinase activity of **cyclin T1-CDK9**, **cyclin B1-CDK1**, **cyclin E-CDK2**, **cyclin D1-CDK4**, **cyclin E-CDK3**, and **p35-CDK5** with IC_{50}s of 1, 2, 3, 4, 5 and 5 nM, respectively; also inhibits GSK-3β, TAK1, Jak2 and MEK1, with IC_{50}s of 3, 5, 50, and 54 nM.



Purity: 98.07%
Clinical Data: Phase 1
Size: 5 mg, 10 mg, 50 mg, 100 mg

SAR502250

Cat. No.: HY-137472

SAR502250 is a potent, selective, ATP competitive, orally active and brain-penetrant inhibitor of **GSK3**, with an IC_{50} of 12 nM for **human GSK-3β**. SAR502250 displays antidepressant-like activity. SAR502250 can be used for the research of Alzheimer's disease (AD).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SB 216763

Cat. No.: HY-12012

SB 216763 is potent, selective and ATP-competitive **GSK-3** inhibitor with IC_{50}s of 34.3 nM for both GSK-3α and GSK-3β.



Purity: 99.30%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

SB 415286

Cat. No.: HY-15438

SB 415286 is a potent and selective cell permeable inhibitor of **GSK-3α**, with an IC_{50} of 77.5 nM, and a K_i of 30.75 nM; SB 415286 is equally effective at inhibiting human **GSK-3α** and **GSK-3β**.



Purity: 99.57%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

TCS 21311

(NIBR3049)

Cat. No.: HY-108264

TCS 21311 (NIBR3049) is a potent, highly selective **JAK3** inhibitor with an IC_{50} of 8 nM, it displays >100-fold selectivity over JAK1, JAK2 and TYK2. TCS 21311 (NIBR3049) inhibits **PKCα**, **PKCθ**, and **GSK3β** with IC_{50}s of 13, 68, and 3 nM, respectively.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

TDZD-8

(GSK-3β Inhibitor I; NP 01139)

Cat. No.: HY-11012

TDZD-8 is an inhibitor of **GSK-3β**, with an IC_{50} of 2 μM; TDZD-8 shows less potent activities against Cdk-1/cyclinB, CK-II, PKA, and PKC, with all IC_{50}s of >100 μM.



Purity: 99.76%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Tideglusib

(NP031112)

Cat. No.: HY-14872

Tideglusib (NP031112) is an irreversible **GSK-3** inhibitor with IC_{50}s of 5 nM and 60 nM for **GSK-3β**^{WT} (1 h preincubation) and **GSK-3β**^{C199A} (1 h preincubation), respectively.



Purity: 99.66%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

TWS119

Cat. No.: HY-10590

TWS119 is a specific inhibitor of **GSK-3β**, with an IC_{50} of 30 nM, and activates the wnt/β-catenin pathway.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

VP3.15 dihydrobromide

Cat. No.: HY-128879A

VP3.15 dihydrobromide is a potent, orally bioavailable and CNS-penetrant dual **phosphodiesterase (PDE)7- glycogen synthase kinase (GSK)3** inhibitor, with IC_{50}s of 1.59 μM and 0.88 μM for PDE7 and GSK-3, respectively.



Purity: 98.22%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg